nodes	percent_of_prediction	percent_of_DWPC	metapath
Ceftazidime—Phlebitis—Carboplatin—esophageal cancer	0.0462	0.0462	CcSEcCtD
Ceftazidime—Prothrombin level increased—Capecitabine—esophageal cancer	0.0289	0.0289	CcSEcCtD
Ceftazidime—Nephropathy toxic—Cisplatin—esophageal cancer	0.028	0.028	CcSEcCtD
Ceftazidime—Reaction gastrointestinal—Methotrexate—esophageal cancer	0.0265	0.0265	CcSEcCtD
Ceftazidime—Myoclonus—Capecitabine—esophageal cancer	0.0197	0.0197	CcSEcCtD
Ceftazidime—Oral candidiasis—Capecitabine—esophageal cancer	0.0187	0.0187	CcSEcCtD
Ceftazidime—Nephropathy—Methotrexate—esophageal cancer	0.0186	0.0186	CcSEcCtD
Ceftazidime—Encephalopathy—Capecitabine—esophageal cancer	0.0185	0.0185	CcSEcCtD
Ceftazidime—Pain—Carboplatin—esophageal cancer	0.0167	0.0167	CcSEcCtD
Ceftazidime—Body temperature increased—Carboplatin—esophageal cancer	0.0155	0.0155	CcSEcCtD
Ceftazidime—Skin exfoliation—Cisplatin—esophageal cancer	0.0154	0.0154	CcSEcCtD
Ceftazidime—Injection site pain—Capecitabine—esophageal cancer	0.0145	0.0145	CcSEcCtD
Ceftazidime—Encephalopathy—Methotrexate—esophageal cancer	0.0138	0.0138	CcSEcCtD
Ceftazidime—Phlebitis—Cisplatin—esophageal cancer	0.0136	0.0136	CcSEcCtD
Ceftazidime—Hyperbilirubinaemia—Capecitabine—esophageal cancer	0.013	0.013	CcSEcCtD
Ceftazidime—Haemolytic anaemia—Cisplatin—esophageal cancer	0.0129	0.0129	CcSEcCtD
Ceftazidime—Inflammation—Capecitabine—esophageal cancer	0.0122	0.0122	CcSEcCtD
Ceftazidime—Colitis—Capecitabine—esophageal cancer	0.0114	0.0114	CcSEcCtD
Ceftazidime—Skin exfoliation—Capecitabine—esophageal cancer	0.0113	0.0113	CcSEcCtD
Ceftazidime—Candida infection—Capecitabine—esophageal cancer	0.0113	0.0113	CcSEcCtD
Ceftazidime—Phlebitis—Capecitabine—esophageal cancer	0.01	0.01	CcSEcCtD
Ceftazidime—Thrombophlebitis—Capecitabine—esophageal cancer	0.00995	0.00995	CcSEcCtD
Ceftazidime—Hepatic function abnormal—Capecitabine—esophageal cancer	0.00986	0.00986	CcSEcCtD
Ceftazidime—Hyperbilirubinaemia—Methotrexate—esophageal cancer	0.00971	0.00971	CcSEcCtD
Ceftazidime—Pancytopenia—Cisplatin—esophageal cancer	0.00959	0.00959	CcSEcCtD
Ceftazidime—Haemolytic anaemia—Capecitabine—esophageal cancer	0.00954	0.00954	CcSEcCtD
Ceftazidime—Hot flush—Capecitabine—esophageal cancer	0.00921	0.00921	CcSEcCtD
Ceftazidime—Menopausal symptoms—Capecitabine—esophageal cancer	0.00913	0.00913	CcSEcCtD
Ceftazidime—Inflammation—Methotrexate—esophageal cancer	0.00911	0.00911	CcSEcCtD
Ceftazidime—Renal impairment—Capecitabine—esophageal cancer	0.00905	0.00905	CcSEcCtD
Ceftazidime—Renal failure—Cisplatin—esophageal cancer	0.00885	0.00885	CcSEcCtD
Ceftazidime—Vaginal inflammation—Methotrexate—esophageal cancer	0.00883	0.00883	CcSEcCtD
Ceftazidime—Lethargy—Capecitabine—esophageal cancer	0.00879	0.00879	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00852	0.00852	CcSEcCtD
Ceftazidime—Skin exfoliation—Methotrexate—esophageal cancer	0.00843	0.00843	CcSEcCtD
Ceftazidime—Vaginal infection—Methotrexate—esophageal cancer	0.00834	0.00834	CcSEcCtD
Ceftazidime—Aplastic anaemia—Methotrexate—esophageal cancer	0.00829	0.00829	CcSEcCtD
Ceftazidime—Coma—Methotrexate—esophageal cancer	0.00807	0.00807	CcSEcCtD
Ceftazidime—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.00776	0.00776	CcSEcCtD
Ceftazidime—Flushing—Cisplatin—esophageal cancer	0.0075	0.0075	CcSEcCtD
Ceftazidime—Thrombophlebitis—Methotrexate—esophageal cancer	0.00741	0.00741	CcSEcCtD
Ceftazidime—Bronchospasm—Capecitabine—esophageal cancer	0.00732	0.00732	CcSEcCtD
Ceftazidime—Immune system disorder—Cisplatin—esophageal cancer	0.0073	0.0073	CcSEcCtD
Ceftazidime—Pancytopenia—Capecitabine—esophageal cancer	0.00707	0.00707	CcSEcCtD
Ceftazidime—Neutropenia—Capecitabine—esophageal cancer	0.00696	0.00696	CcSEcCtD
Ceftazidime—Infestation NOS—Capecitabine—esophageal cancer	0.00664	0.00664	CcSEcCtD
Ceftazidime—Infestation—Capecitabine—esophageal cancer	0.00664	0.00664	CcSEcCtD
Ceftazidime—Vision blurred—Cisplatin—esophageal cancer	0.00663	0.00663	CcSEcCtD
Ceftazidime—Tremor—Cisplatin—esophageal cancer	0.00659	0.00659	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.00658	0.00658	CcSEcCtD
Ceftazidime—Lethargy—Methotrexate—esophageal cancer	0.00654	0.00654	CcSEcCtD
Ceftazidime—Renal failure—Capecitabine—esophageal cancer	0.00652	0.00652	CcSEcCtD
Ceftazidime—Jaundice—Capecitabine—esophageal cancer	0.00647	0.00647	CcSEcCtD
Ceftazidime—Leukopenia—Cisplatin—esophageal cancer	0.0063	0.0063	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Capecitabine—esophageal cancer	0.00628	0.00628	CcSEcCtD
Ceftazidime—Agranulocytosis—Capecitabine—esophageal cancer	0.00619	0.00619	CcSEcCtD
Ceftazidime—Convulsion—Cisplatin—esophageal cancer	0.0061	0.0061	CcSEcCtD
Ceftazidime—Haemoglobin—Capecitabine—esophageal cancer	0.00599	0.00599	CcSEcCtD
Ceftazidime—Haemorrhage—Capecitabine—esophageal cancer	0.00596	0.00596	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00595	0.00595	CcSEcCtD
Ceftazidime—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.00577	0.00577	CcSEcCtD
Ceftazidime—Anaphylactic shock—Cisplatin—esophageal cancer	0.00574	0.00574	CcSEcCtD
Ceftazidime—Erythema multiforme—Capecitabine—esophageal cancer	0.00563	0.00563	CcSEcCtD
Ceftazidime—Nervous system disorder—Cisplatin—esophageal cancer	0.00563	0.00563	CcSEcCtD
Ceftazidime—Thrombocytopenia—Cisplatin—esophageal cancer	0.00562	0.00562	CcSEcCtD
Ceftazidime—Skin disorder—Cisplatin—esophageal cancer	0.00558	0.00558	CcSEcCtD
Ceftazidime—Flushing—Capecitabine—esophageal cancer	0.00553	0.00553	CcSEcCtD
Ceftazidime—Eosinophilia—Methotrexate—esophageal cancer	0.00549	0.00549	CcSEcCtD
Ceftazidime—Angiopathy—Capecitabine—esophageal cancer	0.00541	0.00541	CcSEcCtD
Ceftazidime—Immune system disorder—Capecitabine—esophageal cancer	0.00538	0.00538	CcSEcCtD
Ceftazidime—Hypotension—Cisplatin—esophageal cancer	0.00537	0.00537	CcSEcCtD
Ceftazidime—Pancytopenia—Methotrexate—esophageal cancer	0.00526	0.00526	CcSEcCtD
Ceftazidime—Neutropenia—Methotrexate—esophageal cancer	0.00518	0.00518	CcSEcCtD
Ceftazidime—Paraesthesia—Cisplatin—esophageal cancer	0.00516	0.00516	CcSEcCtD
Ceftazidime—Dysgeusia—Capecitabine—esophageal cancer	0.00508	0.00508	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00496	0.00496	CcSEcCtD
Ceftazidime—Infestation NOS—Methotrexate—esophageal cancer	0.00494	0.00494	CcSEcCtD
Ceftazidime—Infestation—Methotrexate—esophageal cancer	0.00494	0.00494	CcSEcCtD
Ceftazidime—Pain—Cisplatin—esophageal cancer	0.00491	0.00491	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.0049	0.0049	CcSEcCtD
Ceftazidime—Vision blurred—Capecitabine—esophageal cancer	0.00489	0.00489	CcSEcCtD
Ceftazidime—Tremor—Capecitabine—esophageal cancer	0.00486	0.00486	CcSEcCtD
Ceftazidime—Renal failure—Methotrexate—esophageal cancer	0.00486	0.00486	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Methotrexate—esophageal cancer	0.00467	0.00467	CcSEcCtD
Ceftazidime—Leukopenia—Capecitabine—esophageal cancer	0.00464	0.00464	CcSEcCtD
Ceftazidime—Agranulocytosis—Methotrexate—esophageal cancer	0.00461	0.00461	CcSEcCtD
Ceftazidime—Body temperature increased—Cisplatin—esophageal cancer	0.00454	0.00454	CcSEcCtD
Ceftazidime—Haemoglobin—Methotrexate—esophageal cancer	0.00446	0.00446	CcSEcCtD
Ceftazidime—Haemorrhage—Methotrexate—esophageal cancer	0.00444	0.00444	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00439	0.00439	CcSEcCtD
Ceftazidime—Hypersensitivity—Cisplatin—esophageal cancer	0.00423	0.00423	CcSEcCtD
Ceftazidime—Erythema multiforme—Methotrexate—esophageal cancer	0.00419	0.00419	CcSEcCtD
Ceftazidime—Nervous system disorder—Capecitabine—esophageal cancer	0.00415	0.00415	CcSEcCtD
Ceftazidime—Thrombocytopenia—Capecitabine—esophageal cancer	0.00415	0.00415	CcSEcCtD
Ceftazidime—Skin disorder—Capecitabine—esophageal cancer	0.00411	0.00411	CcSEcCtD
Ceftazidime—Angiopathy—Methotrexate—esophageal cancer	0.00402	0.00402	CcSEcCtD
Ceftazidime—Immune system disorder—Methotrexate—esophageal cancer	0.00401	0.00401	CcSEcCtD
Ceftazidime—Hypotension—Capecitabine—esophageal cancer	0.00396	0.00396	CcSEcCtD
Ceftazidime—Diarrhoea—Cisplatin—esophageal cancer	0.00393	0.00393	CcSEcCtD
Ceftazidime—Paraesthesia—Capecitabine—esophageal cancer	0.0038	0.0038	CcSEcCtD
Ceftazidime—Dysgeusia—Methotrexate—esophageal cancer	0.00378	0.00378	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00365	0.00365	CcSEcCtD
Ceftazidime—Vomiting—Cisplatin—esophageal cancer	0.00365	0.00365	CcSEcCtD
Ceftazidime—Vision blurred—Methotrexate—esophageal cancer	0.00364	0.00364	CcSEcCtD
Ceftazidime—Rash—Cisplatin—esophageal cancer	0.00362	0.00362	CcSEcCtD
Ceftazidime—Pain—Capecitabine—esophageal cancer	0.00362	0.00362	CcSEcCtD
Ceftazidime—Dermatitis—Cisplatin—esophageal cancer	0.00362	0.00362	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00346	0.00346	CcSEcCtD
Ceftazidime—Leukopenia—Methotrexate—esophageal cancer	0.00346	0.00346	CcSEcCtD
Ceftazidime—Nausea—Cisplatin—esophageal cancer	0.00341	0.00341	CcSEcCtD
Ceftazidime—Urticaria—Capecitabine—esophageal cancer	0.00336	0.00336	CcSEcCtD
Ceftazidime—Abdominal pain—Capecitabine—esophageal cancer	0.00335	0.00335	CcSEcCtD
Ceftazidime—Body temperature increased—Capecitabine—esophageal cancer	0.00335	0.00335	CcSEcCtD
Ceftazidime—Convulsion—Methotrexate—esophageal cancer	0.00335	0.00335	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00326	0.00326	CcSEcCtD
Ceftazidime—Anaphylactic shock—Methotrexate—esophageal cancer	0.00315	0.00315	CcSEcCtD
Ceftazidime—Hypersensitivity—Capecitabine—esophageal cancer	0.00312	0.00312	CcSEcCtD
Ceftazidime—Nervous system disorder—Methotrexate—esophageal cancer	0.00309	0.00309	CcSEcCtD
Ceftazidime—Thrombocytopenia—Methotrexate—esophageal cancer	0.00309	0.00309	CcSEcCtD
Ceftazidime—Skin disorder—Methotrexate—esophageal cancer	0.00306	0.00306	CcSEcCtD
Ceftazidime—Pruritus—Capecitabine—esophageal cancer	0.003	0.003	CcSEcCtD
Ceftazidime—Hypotension—Methotrexate—esophageal cancer	0.00294	0.00294	CcSEcCtD
Ceftazidime—Diarrhoea—Capecitabine—esophageal cancer	0.0029	0.0029	CcSEcCtD
Ceftazidime—Paraesthesia—Methotrexate—esophageal cancer	0.00283	0.00283	CcSEcCtD
Ceftazidime—Dizziness—Capecitabine—esophageal cancer	0.0028	0.0028	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00272	0.00272	CcSEcCtD
Ceftazidime—Pain—Methotrexate—esophageal cancer	0.00269	0.00269	CcSEcCtD
Ceftazidime—Vomiting—Capecitabine—esophageal cancer	0.00269	0.00269	CcSEcCtD
Ceftazidime—Rash—Capecitabine—esophageal cancer	0.00267	0.00267	CcSEcCtD
Ceftazidime—Dermatitis—Capecitabine—esophageal cancer	0.00267	0.00267	CcSEcCtD
Ceftazidime—Headache—Capecitabine—esophageal cancer	0.00265	0.00265	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00258	0.00258	CcSEcCtD
Ceftazidime—Nausea—Capecitabine—esophageal cancer	0.00251	0.00251	CcSEcCtD
Ceftazidime—Urticaria—Methotrexate—esophageal cancer	0.0025	0.0025	CcSEcCtD
Ceftazidime—Abdominal pain—Methotrexate—esophageal cancer	0.00249	0.00249	CcSEcCtD
Ceftazidime—Body temperature increased—Methotrexate—esophageal cancer	0.00249	0.00249	CcSEcCtD
Ceftazidime—Hypersensitivity—Methotrexate—esophageal cancer	0.00232	0.00232	CcSEcCtD
Ceftazidime—Pruritus—Methotrexate—esophageal cancer	0.00223	0.00223	CcSEcCtD
Ceftazidime—Diarrhoea—Methotrexate—esophageal cancer	0.00216	0.00216	CcSEcCtD
Ceftazidime—Dizziness—Methotrexate—esophageal cancer	0.00208	0.00208	CcSEcCtD
Ceftazidime—Vomiting—Methotrexate—esophageal cancer	0.002	0.002	CcSEcCtD
Ceftazidime—Rash—Methotrexate—esophageal cancer	0.00199	0.00199	CcSEcCtD
Ceftazidime—Dermatitis—Methotrexate—esophageal cancer	0.00199	0.00199	CcSEcCtD
Ceftazidime—Headache—Methotrexate—esophageal cancer	0.00197	0.00197	CcSEcCtD
Ceftazidime—Nausea—Methotrexate—esophageal cancer	0.00187	0.00187	CcSEcCtD
